Immunic

IMMUNIC INC

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.

YelpLogoAugust2021

News

Initiation

Markets

Analyst Ratings

Trading Ideas

BHVN

COYA

IMUX

YELP

This Yelp Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday

Long Ideas

Penny Stocks

Small Cap

Insider Trades

Pre-Market Outlook

FRTX

The Dow Jones index closed lower by over 20 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#39;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Immunic And 2 Other Stocks Under $2 Insiders Are Buying

Movers

Immunic, Inc. (NASDAQ: IMUX) shares are roughly flat following strength early Friday after the company announced a three-tranche private placement of up to $240 million.

What&#39;s Going On With Immunic Stock?

Immunic Inc

Press Releases

Immunic, Inc. to Participate in Scientific and Industry Conferences in April

Offerings

Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments

Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments

Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial

Immunic to Participate in Scientific and Industry Conferences in May

Immunic, Inc. Announces Proposed Public Offering

Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering

Immunic to Participate in Investor, Scientific and Industry Conferences in June

Immunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public Offering

Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS

Adagene Inc. - ADS, each representing 1.25 ordinary shares

Adagene

Adaptimmune Therapeutics plc - American Depositary Shares

Adaptimmune Therapeutics

Armata Pharmaceuticals, Inc. Common Stock

Armata Pharmaceuticals

Alterity Therapeutics Limited - American Depositary Shares

Alterity Therapeutics

BeyondSpring

Climb Bio

Citius Oncology

Elutia

Forte Biosciences

Galectin Therapeutics Inc. - Common Stock

Galectin Therapeutics

Genenta Science S.p.A. - American Depositary Shares

Genenta Science

IGM Biosciences

Immuneering Corporation - Class A Common Stock

Immuneering

Inovio Pharmaceuticals, Inc. - Common Stock

Inovio Pharmaceuticals

MediciNova

OncoCyte

Outlook Therapeutics, Inc. - Common Stock

Outlook Therapeutics

PDS Biotechnology Corporation - Common Stock

PDS Biotechnology

Pyxis Oncology

Skye Bioscience

Surrozen

Sutro Biopharma

Vistagen Therapeutics, Inc. - Common Stock

Vistagen Therapeutics

Whitehawk Therapeutics, Inc. - Common Stock

Whitehawk Therapeutics

Zura Bio Limited - Class A Ordinary shares

Zura Bio

D. Boral Capital

B. Riley Securities

HC Wainwright & Co.

EF Hutton

Leerink Partners

Comments

Immunic

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell